Bruker (BRKR) Lifted to “Buy” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Bruker (NASDAQ:BRKR) from a hold rating to a buy rating in a research report sent to investors on Wednesday.

Other research analysts also recently issued reports about the company. UBS Group assumed coverage on Bruker in a research note on Tuesday, October 9th. They issued a sell rating and a $30.00 price target for the company. They noted that the move was a valuation call. ValuEngine downgraded Bruker from a hold rating to a sell rating in a research note on Wednesday, July 11th. Morgan Stanley raised their price target on Bruker from $29.00 to $31.00 and gave the company an equal weight rating in a research note on Friday, August 3rd. Finally, Zacks Investment Research downgraded Bruker from a hold rating to a sell rating in a research note on Tuesday, July 24th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $34.63.

Bruker stock traded down $1.07 during midday trading on Wednesday, reaching $33.83. The stock had a trading volume of 736,982 shares, compared to its average volume of 718,089. Bruker has a 1-year low of $28.13 and a 1-year high of $36.53. The firm has a market cap of $5.40 billion, a PE ratio of 27.96, a P/E/G ratio of 2.11 and a beta of 1.34. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.27 and a current ratio of 2.22.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, November 1st. The medical research company reported $0.37 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.07. The firm had revenue of $466.60 million during the quarter, compared to the consensus estimate of $451.88 million. Bruker had a return on equity of 27.96% and a net margin of 5.24%. The business’s revenue was up 7.1% compared to the same quarter last year. During the same period last year, the company earned $0.29 earnings per share. As a group, equities research analysts predict that Bruker will post 1.4 EPS for the current year.

Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in shares of Bruker during the 2nd quarter worth approximately $101,000. Sun Life Financial INC bought a new position in shares of Bruker during the 2nd quarter worth approximately $163,000. Crossmark Global Holdings Inc. bought a new position in shares of Bruker during the 3rd quarter worth approximately $205,000. Private Advisor Group LLC bought a new position in shares of Bruker during the 3rd quarter worth approximately $210,000. Finally, First Hawaiian Bank bought a new position in shares of Bruker during the 3rd quarter worth approximately $248,000. Hedge funds and other institutional investors own 64.86% of the company’s stock.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Article: Why investors pay attention to retained earnings

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.